As scientists working with PCI at the Radium Hospital are bound by overriding contracts, PCI opted for inclusion of the commercial potential in this research. The work clearly shows the potential for the combination of PCI and siRNA/PNA for targeted treatment of cancer by modifying the expression of selected target genes. The company issued a stock exchange
note related to the agreemnt. The PNA article is
available from the publisher, or on request, while the siRNA article has been accepted for publication. This research is mostly part of the doctoral work of Sigurd Bøe. Some information on his research may be inspected on
Sigurds page. And some
illustrations of the mechanisms may also be found.